This clinical trial is focused on finding treatments to slow the progression of Chronic Kidney Disease (CKD). The study will investigate the effects of a medication called Kerendia, which contains the active substance finerenone. Kerendia is available in two forms: 10 mg and 20 mg film-coated tablets. The purpose of the study is to determine if Kerendia can reduce the rate of kidney function decline in patients with CKD, compared to a placebo.
Participants in the study will receive either Kerendia or a placebo, taken orally as a tablet. The study will last for a period of up to 24 months. During this time, participants will continue to receive their standard care for CKD. The study aims to observe changes in kidney function, specifically looking at the estimated glomerular filtration rate (eGFR), which is a measure of how well the kidneys are working. The study will also monitor other health outcomes, such as changes in protein levels in the urine and the occurrence of cardiovascular events like heart attacks or strokes.
The trial will help researchers understand if Kerendia can effectively slow down the progression of CKD and improve the quality of life for those affected by this condition. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the medication’s effects. The findings from this study could lead to better treatment options for people living with CKD.
Greece 
Spain 
